I-Mab ADR (IMAB)

$4.63 -0.01 (-0.22%)
Market Cap 378.09M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,517,300
Avg Vol 1,822,668
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 22%
Beta 1.45
Analysts Strong Sell
Price Target $8.60

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
LabPsycho
LabPsycho Mar. 30 at 3:18 PM
$IMAB Like I posted about 2 weeks ago when this was $3 ish. Data looks good but not seeing a big differentiator here...and the location now.
0 · Reply
LabPsycho
LabPsycho Mar. 19 at 2:30 PM
$IMAB IMO, I am not seeing significant product differentiation for either of their drugs. Maybe a little better but could get lost in the crowd. And I do not know if I am understanding but did they move from Asia to USA back to Hong Kong? Watching but I think this like many biotechs going to be giving up their 50-1200% gains the past 11 months. I'd like to see these get well below cash like the good ole days. Valuations and risk / reward, esp. with war and inflation increasing not a good look currently IMO
1 · Reply
GamblingFerret
GamblingFerret Mar. 19 at 2:24 PM
$IMAB Remarkable news lately: Novabridge and FDA aligned on potential accelerated approval path for Givastomig. Phase 3 is intended to start in Q4 2026 based on phase 1b data. The recently started phase 2 was intended to deliver data in mid 2027, so this news speeds up development at least 1 year. Giva has market potential of roughly 5 billion, Novabridge owns 50% of the Asset and is in development lead. https://www.novabridge.com/news-releases/news-release-details/novabridge-announces-productive-fda-type-b-meeting-potential
0 · Reply
aletz
aletz Mar. 13 at 10:31 AM
$IMAB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #5 pick for March Week 3. Visit the link for more detail.
1 · Reply
Stocksman45
Stocksman45 Mar. 10 at 11:49 PM
$IMAB very good news on their new acquisition the eye drug yesterday. And of course their mainstay Givistomag is the big gun.
0 · Reply
sgtcw1
sgtcw1 Mar. 5 at 4:50 PM
$IMAB not a bad day!
0 · Reply
Stocksman45
Stocksman45 Feb. 9 at 8:43 PM
$IMAB Very detailed presentation on Novabridge Biosciences. Worth a read: https://archive.fast-edgar.com/20260206/AU22J22CZZ2RI2Z2229N2CYQGRPH4Z22D282/nbp-ex99_1.htm
0 · Reply
Stocksman45
Stocksman45 Jan. 27 at 5:45 PM
$IMAB Lots of insider buying. News forthcoming in the next month or so?
0 · Reply
sgtcw1
sgtcw1 Jan. 20 at 2:34 PM
$IMAB https://finance.yahoo.com/news/novabridge-announces-open-market-purchases-120000363.html
0 · Reply
HephaestusH
HephaestusH Dec. 27 at 4:46 AM
$IMAB Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. If milestones become dependable, sentiment could re‑rate quickly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
Latest News on IMAB
No data available.
LabPsycho
LabPsycho Mar. 30 at 3:18 PM
$IMAB Like I posted about 2 weeks ago when this was $3 ish. Data looks good but not seeing a big differentiator here...and the location now.
0 · Reply
LabPsycho
LabPsycho Mar. 19 at 2:30 PM
$IMAB IMO, I am not seeing significant product differentiation for either of their drugs. Maybe a little better but could get lost in the crowd. And I do not know if I am understanding but did they move from Asia to USA back to Hong Kong? Watching but I think this like many biotechs going to be giving up their 50-1200% gains the past 11 months. I'd like to see these get well below cash like the good ole days. Valuations and risk / reward, esp. with war and inflation increasing not a good look currently IMO
1 · Reply
GamblingFerret
GamblingFerret Mar. 19 at 2:24 PM
$IMAB Remarkable news lately: Novabridge and FDA aligned on potential accelerated approval path for Givastomig. Phase 3 is intended to start in Q4 2026 based on phase 1b data. The recently started phase 2 was intended to deliver data in mid 2027, so this news speeds up development at least 1 year. Giva has market potential of roughly 5 billion, Novabridge owns 50% of the Asset and is in development lead. https://www.novabridge.com/news-releases/news-release-details/novabridge-announces-productive-fda-type-b-meeting-potential
0 · Reply
aletz
aletz Mar. 13 at 10:31 AM
$IMAB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #5 pick for March Week 3. Visit the link for more detail.
1 · Reply
Stocksman45
Stocksman45 Mar. 10 at 11:49 PM
$IMAB very good news on their new acquisition the eye drug yesterday. And of course their mainstay Givistomag is the big gun.
0 · Reply
sgtcw1
sgtcw1 Mar. 5 at 4:50 PM
$IMAB not a bad day!
0 · Reply
Stocksman45
Stocksman45 Feb. 9 at 8:43 PM
$IMAB Very detailed presentation on Novabridge Biosciences. Worth a read: https://archive.fast-edgar.com/20260206/AU22J22CZZ2RI2Z2229N2CYQGRPH4Z22D282/nbp-ex99_1.htm
0 · Reply
Stocksman45
Stocksman45 Jan. 27 at 5:45 PM
$IMAB Lots of insider buying. News forthcoming in the next month or so?
0 · Reply
sgtcw1
sgtcw1 Jan. 20 at 2:34 PM
$IMAB https://finance.yahoo.com/news/novabridge-announces-open-market-purchases-120000363.html
0 · Reply
HephaestusH
HephaestusH Dec. 27 at 4:46 AM
$IMAB Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. If milestones become dependable, sentiment could re‑rate quickly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
PalmHill
PalmHill Dec. 12 at 12:16 AM
$IMAB another dishonest pharma… like so many.
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Nov. 4 at 2:24 PM
$ONCY Advancing Toward a Platform Immunotherapy in GI Cancers 🧬 📰 Fresh Press Release November 4 : Oncolytics Biotech has established a Gastrointestinal Tumor Scientific Advisory Board to guide pelareorep’s clinical and regulatory strategy across pancreatic, colorectal, and anal cancers. Inaugural Members: ➡️ Dr. Sanjay Goel ➡️ Dr. Deva Mahalingam ➡️ Dr. Dirk Arnold These leading oncology experts have been directly involved in pelareorep based clinical trials. Why it matters: This move reinforces Oncolytics’ mission to position pelareorep as the first true platform immunotherapy in gastrointestinal oncology. With seasoned leadership, expanding clinical validation, and the creation of this world-class advisory board, Oncolytics Biotech is steadily converting scientific promise into commercial potential. 📈 Technical Snapshot: - Support: $1.08 - Breakout levels: $1.19 ➡ $1.33 ➡ $1.42 ➡ $1.47 ➡ $1.51 Communicated Disclaimer: http://bit.ly/4qzOlZb Sector Peers: $GNLX $IMAB $DBVT
2 · Reply
Stocksman45
Stocksman45 Nov. 4 at 12:55 AM
$IMAB https://finance.yahoo.com/news/novabridge-subsidiary-visara-assigns-exclusive-081500758.html
0 · Reply
4th_and_50
4th_and_50 Oct. 31 at 5:06 PM
$IMAB $NBP.X should have changed name to $SNM.X Smoke ‘N Mirrors, but it was taken
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:40 PM
$FDMT: $IMAB tried the name change to $NBP.X — still sank. Cosmetic changes don’t defy gravity.
0 · Reply
grizzly3
grizzly3 Oct. 30 at 6:25 PM
$IMAB changing its name to $NBP.X won’t change its fate. You can repaint the house, but the cracks in the foundation are still there.
0 · Reply
Yusufkadiani
Yusufkadiani Oct. 30 at 5:52 PM
$IMAB what’s happening with this?
0 · Reply
DARKP00L
DARKP00L Oct. 29 at 1:43 PM
$IMAB 09:20 on Oct. 29 2025 I-Mab Changes Name To NovaBridge Biosciences; To Trade Under New Name, NBP Ticker, Effective Oct. 30 #tradeideas
1 · Reply
sgtcw1
sgtcw1 Oct. 28 at 3:01 PM
$IMAB
0 · Reply
Stocksman45
Stocksman45 Oct. 24 at 8:14 PM
$IMAB https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 9:44 AM
BTIG updates rating for I-MAB ( $IMAB ) to Buy, target set at 9.
0 · Reply